Self-Illuminating Nanoagonist Simultaneously Induces Dual Cell Death Pathways via Death Receptor Clustering for...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapeutics

Background:

• Targeting death receptor 5 (DR5) is a promising strategy for cancer therapy.
• DR5 clustering can initiate apoptosis in cancer cells.
• Developing effective delivery systems for DR5-targeting agents is crucial.

Purpose of the Study:

• To design and evaluate a tumor microenvironment-responsive, self-illuminating nanoagonist for enhanced DR5 clustering.
• To investigate the dual tumor cell death pathways induced by the nanoagonist.
• To assess the in vivo antitumor efficacy and immune response modulation.

Main Methods:

• Conjugation of DR5 ligand peptides onto self-illuminating nanoparticles with cross-linking capabilities.
• Utilizing a tumor microenvironment H2O2-responsive system.
• Employing photo-cross-linking to enhance receptor-ligand interactions.
• Evaluating apoptosis, immunogenic cell death, and antitumor effects in preclinical models.

Main Results:

• The nanoagonist effectively enhances DR5 clustering and initiates the extrinsic apoptosis pathway.
• Dual tumor cell death pathways, including immunogenic cell death, were induced.
• Significant tumor-specific immune responses were observed.
• The nanoagonist demonstrated enhanced antitumor efficacy with minimized systemic toxicity.

Conclusions:

• The developed H2O2-responsive self-illuminating nanoagonist is a potent strategy for dual tumor cell death induction via DR5 clustering.
• This approach offers a promising platform for tumor-specific cancer therapeutics with improved immune activation.
• The nanoagonist shows potential for enhanced antitumor efficacy and reduced adverse effects in cancer treatment.